<span item_type="fundamental" item_id="ee1f3d9b5f4129d2f97588647b8d94c1" counter_id="ST/US/NXPLW" env="prod"></span><span item_type="announcement" item_id="582340130792412289" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 13.75 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.08.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.063 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Consolidated revenue for Q3 2025 was approximately $13.8 million, a decrease from $15.4 million in Q3 2024, primarily due to a decline in Healthcare Operations revenue.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross profit margin for Q3 2025 declined to approximately 19.9% from 23.2% in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li><li>Operating expenses decreased to approximately $4.7 million in Q3 2025 from $7.8 million in Q3 2024, excluding non-recurring expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li><li>Net loss attributable to NextPlat Corp common shareholders for Q3 2025 decreased approximately 48% to approximately $2.2 million, or - $0.08 per diluted share, compared to a net loss of approximately $4.2 million, or - $0.22 per diluted share in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>The Company ended Q3 2025 with approximately $13.9 million in cash.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>During Q3 2025, NextPlat began repurchasing its common shares, with a total of 130,549 shares repurchased and held as treasury stock.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>NextPlat anticipates sequential increases in 340B prescription volumes starting in Q4 2025 due to improved prescription volume within the Healthcare segment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li><li>The Company expects further reductions in operating expenses contributing to continued improvement going forward.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li><li>Increased activity and momentum in prescription volumes are anticipated to drive significant sequential increases in Q4 2025 and into 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1058307/000143774925034668/ex_854774.htm"></span></li></ul>

NEXTPLAT CORP C/WTS 02/06/2027 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 13.75 M